View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
November 25, 2020

Coronavirus company news summary – Lilly signs a 26,0000 dose supply deal with Canada – Moderna finalises vaccine supply deal with the EC

By Allie Nawrat

25 November 2020 

Independent biomedical research and treatment centre for life-threatening diseases City of Hope initiated a Phase I clinical trial of its investigational SARS-CoV-2 vaccine among healthy participants between the ages of 18 and 55 years with no prior SARS-CoV-2 infection.

Allero Therapeutics and Abbreos have announced a collaboration to clinically test the  latter’s novel OroMucosal ImmunoGlobulin (OMIG) that addresses medical conditions associated with lethal amounts of pro-inflammatory cytokines and chemokines. The first focus of the initiative is to treat patients who are likely to suffer from Covid-19-associated acute respiratory distress syndrome (ARDS), and if not treated, require intensive care and ventilation.

Eli Lilly has signed a $32.5m agreement with Canada to supply 26,000 doses of  its antibody drug bamlanivimab to treat Covid-19 patients. The treatment was developed by Canadian biotech company AbCellera and is expected to be supplied to Canada between December and February.

A European Union (EU) official confirmed that the European Commission has signed a vaccine supply deal with Moderna. Moderna’s mRNA-1273 vaccine candidate met its primary efficacy endpoint in a Phase III COVE study with 94.5% efficacy.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology